News and Trends 20 Sep 2022 Biopharma company Faron announces escalation data cancer treatment study A clinical stage biopharma company has announced further dose escalation data from its phase 1/2 study looking at the safety and efficacy of a monotherapy in ten different hard-to-treat cancers. Latest progress from Faron Pharma’s MATINS (Macrophage Antibody To INhibit immune Suppression) study was focused on higher dose levels and frequencies to finalize the dose […] September 20, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Regen BioPharma files patent on new RNA/DNA-based approach to cancer immunotherapy Regen BioPharma, Inc. has filed a provisional patent application with the USPTO entitled “Dual Checkpoint Inhibitor Aptamer Based Therapeutics.” The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes that regulate T cells and cancer cells such as NR2F6 and Survivin. The company says this platform […] September 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Dyania Health raises $5.3M to help speed up clinical trials Dyania Health was founded in 2019 to address a significant and unsolved problem for clinical trials. That is, the process of manual chart review to pre-screening patients for clinical research is cumbersome and time-consuming. The process to match patients on very specific and time-sensitive clinical trial criteria typically takes 18 to 24 months for most […] September 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 GENFIT to acquire Versantis to expand liver disease portfolio GENFIT has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases. GENFIT said the acquisition fits its strategic vision of becoming a global leader in ACLF (acute-on-chronic […] September 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Biologics manufacturing facility launched by Evotec SE in Toulouse Construction of a biologics manufacturing facility commenced on Friday (September 16). It is being built by Evotec at its Campus Curie in Toulouse, is the second facility of its kind, and the first in Europe. It will use Just – Evotec Biologics’ flexible J.POD technology to deliver clinical and commercial manufacturing capacity for biologics. Therapeutic […] September 19, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA approves Heron Therapeutics’ post-op nausea and vomiting drug Heron Therapeutics, Inc. says the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults. Heron Therapeutics’ APONVIE is the first and only IV formulation of aprepitant for PONV prevention. Administered via a single 30-second IV injection, APONVIE reaches […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The company said the ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development […] September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Marengo advancing its lead TCR activator into clinic after FDA clearance Marengo Therapeutics is advancing its lead TCR activator, STAR0602, into clinic following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). STAR0602 is a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical […] September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 Novome Biotechnologies raises $43.5M for therapeutically engineered microbes pipeline U.S. biotech company Novome Biotechnologies, Inc., has closed a $43.5 million series B financing round. The financing was led by Tencent, and includes new investors University of Minnesota, Navian Investments, Colorcon Ventures and Touchdown Ventures. Existing investors DCVC Bio, 5AM Ventures, Alta Partners and Alexandria Venture Investments also participated. The proceeds will be used to […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2022 New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix (ECM) biomarker, PRO-C6, as a potential next-generation biomarker for trial enrichment in patients with heart failure with preserved ejection fraction (HFpEF). The paper is entitled “Endotrophin, a collagen VI formation-derived peptide, in Heart Failure.” The […] September 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Recursion adds FAP and C. diff clinical trials Recursion Pharmaceuticals has initiated two additional clinical trials including its first in-house generated new chemical entity to enter the clinic. The phase 2 TUPELO clinical trial is evaluating REC-4881 for the potential treatment of familial adenomatous polyposis (FAP) in patients who have previously undergone a colectomy/proctocolectomy. REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule […] September 14, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email